GILD (Gilead Sciences, Inc.) Stock Financials & Earnings

Company Info & Key Metrics

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company ...

CEODaniel O'Day

Country🇺🇸 United States

ExchangeNASDAQ

IPOJan 22, 1992

www.gilead.com

Revenue$7.9B

YoY Growth+4.7%

QoQ Growth+2.0%

Net Income$2.2B

EPS$1.74

Free Cash Flow$3.1B

Gross Margin86.8%

Op. Margin37.4%

Net Margin27.5%

FCF Margin39.4%

Rev Multiple (TTM)6.2x

P/E Ratio (TTM)21.6x

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$6.4B	$5.0B	$1.7B
Q2 23	$6.6B	$5.2B	$1.7B
Q3 23	$7.0B	$5.5B	$2.6B
Q4 23	$7.1B	$5.0B	$1.6B
Q1 24	$6.7B	$5.1B	-$4.3B
Q2 24	$7.0B	$5.4B	$2.6B
Q3 24	$7.5B	$6.0B	$888M
Q4 24	$7.6B	$6.0B	$2.5B
Q1 25	$6.7B	$5.1B	$2.2B
Q2 25	$7.1B	$5.6B	$2.5B
Q3 25	$7.8B	$6.2B	$3.3B
Q4 25	$7.9B	$6.9B	$3.0B

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	6.8x	32.8x
Q2 23	6.7x	33.4x
Q3 23	6.7x	31.2x
Q4 23	6.8x	32.4x
Q1 24	6.7x	378.9x
Q2 24	6.6x	174.2x
Q3 24	6.5x	1455.5x
Q4 24	6.4x	382.1x
Q1 25	6.4x	30.7x
Q2 25	6.4x	29.1x
Q3 25	6.3x	22.6x
Q4 25	6.2x	21.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$1.7B	$1.6B
Q2 23	$2.3B	$2.2B
Q3 23	$1.8B	$1.6B
Q4 23	$2.2B	$2.0B
Q1 24	$2.2B	$2.1B
Q2 24	$1.3B	$1.2B
Q3 24	$4.3B	$4.2B
Q4 24	$3.0B	$2.8B
Q1 25	$1.8B	$1.7B
Q2 25	$827M	$720M
Q3 25	$4.1B	$4.0B
Q4 25	$3.3B	$3.1B

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$109M
Q2 23	$139M
Q3 23	$122M
Q4 23	$215M
Q1 24	$105M
Q2 24	$130M
Q3 24	$141M
Q4 24	$147M
Q1 25	$104M
Q2 25	$107M
Q3 25	$147M
Q4 25	$205M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-3.6%	-27.3%
Q2 23	+5.4%	+16.6%
Q3 23	+0.1%	+5.3%
Q4 23	-3.7%	+7.4%
Q1 24	+5.3%	+136.9%
Q2 24	+5.4%	-12.7%
Q3 24	+7.0%	+50.4%
Q4 24	+6.4%	-7.0%
Q1 25	-0.3%	-59.8%
Q2 25	+1.8%	+6.9%
Q3 25	+3.0%	-33.3%
Q4 25	+4.7%	-3.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$165M	2.6%
Q2 23	$198M	3.0%
Q3 23	$202M	2.9%
Q4 23	$201M	2.8%
Q1 24	$187M	2.8%
Q2 24	$210M	3.0%
Q3 24	$216M	2.9%
Q4 24	$222M	2.9%
Q1 25	$209M	3.1%
Q2 25	$225M	3.2%
Q3 25	$230M	3.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$1.4B	—	—	$1.3B
Q2 23	$1.4B	—	—	$1.8B
Q3 23	$1.5B	—	—	$1.3B
Q4 23	$1.4B	$754M	$826M	—
Q1 24	$1.5B	$632M	$743M	—
Q2 24	$1.4B	$572M	$805M	—
Q3 24	$1.4B	$442M	$968M	—
Q4 24	$1.6B	$992M	$869M	—
Q1 25	$1.4B	$505M	$753M	—
Q2 25	$1.5B	$501M	$864M	—
Q3 25	$1.3B	$528M	$829M	—
Q4 25	$1.6B	—	—	$1.8B

Revenue Segments

Quarter	Cell Therapy Products, Total Cell Therapy Product Sales	Hepatitis B Virus / Hepatitis Delta Virus Product	Other Hepatitis C Virus Products	Other Products, Total Other product sales	Products, Other HIV	Trodelvy	Veklury	Liver Disease
Q1 23	$896M	$230M	$45M	$199M	$4.2B	$222M	$573M	—
Q2 23	$937M	$259M	$40M	$243M	$4.6B	$260M	$256M	—
Q3 23	$973M	$269M	$38M	$216M	$4.7B	$283M	$636M	—
Q1 24	$960M	—	—	$224M	$4.3B	$309M	$555M	—
Q3 24	$970M	—	—	$201M	$5.1B	$332M	$692M	—
Q1 25	$464M	—	—	$209M	$4.6B	$293M	$302M	$758M
Q2 25	$577M	—	—	$202M	$5.1B	$364M	$121M	$795M

Revenue by Geography

Quarter	Europe	Other International	United States
Q1 23	$1.1B	$821M	$4.5B
Q2 23	$1.0B	$789M	$4.8B
Q3 23	$1.0B	$993M	$5.0B
Q4 23	$1.2B	$765M	$5.2B
Q1 24	$1.2B	$894M	$4.6B
Q2 24	$1.1B	$879M	$4.9B
Q3 24	$1.2B	$929M	$5.5B
Q4 24	$1.2B	$827M	$5.6B
Q1 25	$1.1B	$915M	$4.7B
Q2 25	$1.2B	$842M	$5.3B
Q3 25	$1.6B	$933M	$5.3B
Q4 25	$1.2B	$813M	$5.7B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$4.9B	$936M	$5.9B
Q2 23	$5.7B	$963M	$6.7B
Q3 23	$5.7B	$1.2B	$6.9B
Q4 23	$6.1B	$2.3B	$8.3B
Q1 24	$4.7B	$1.3B	$6.1B
Q2 24	$2.8B	$1.4B	$4.2B
Q3 24	$5.0B	$1.7B	$6.7B
Q4 24	$10.0B	$1.6B	$11.6B
Q1 25	$7.9B	$0	$7.9B
Q2 25	$5.1B	$69M	$5.2B
Q3 25	$7.3B	$19M	$7.3B
Q4 25	$7.6B	$3.0B	$10.6B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	1.26B	-0.2%
Q2 23	1.26B	-0.2%
Q3 23	1.26B	-0.1%
Q4 23	1.26B	-0.1%
Q1 24	1.25B	-0.7%
Q2 24	1.25B	+0.3%
Q3 24	1.25B	+0.2%
Q4 24	1.26B	+0.4%
Q1 25	1.26B	+0.0%
Q2 25	1.25B	-0.3%
Q3 25	1.25B	-0.1%
Q4 25	1.25B	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$4M	7K
FY 15	$4M	8K
FY 16	$3M	9K
FY 17	$3M	10K
FY 18	$2M	11K
FY 19	$2M	12K
FY 20	$2M	14K
FY 21	$2M	14K
FY 22	$2M	17K
FY 23	$2M	18K
FY 24	$2M	18K
FY 25	$2M	17K